We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection led to 22% weight loss measured at 36 weeks. Last month, Metsera raised $275 million from its ...

Metsera has shared positive topline results from the Phase 2a trial, reporting up to 11.3% mean placebo-adjusted weight loss ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Metsera has shared positive topline results from the Phase 2a trial, reporting up to 11.3% mean placebo-adjusted weight loss at 12 weeks, with no evidence of a plateau. These results demonstrate ...

Second, in 2024 we entered the high-growth weight loss and obesity space, a new category for Amneal, through a strategic collaboration with Metsera, a clinical stage biotech company developing ...

Amneal Pharmaceuticals Inc (AMRX) reports robust financial performance with double-digit growth across key segments and strategic moves into new markets.